COLL vs. SRRK, VKTX, MIRM, LNTH, ADMA, ACAD, ZLAB, QURE, CGON, and AAPG
Should you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Scholar Rock (SRRK), Viking Therapeutics (VKTX), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), ADMA Biologics (ADMA), ACADIA Pharmaceuticals (ACAD), Zai Lab (ZLAB), uniQure (QURE), CG Oncology (CGON), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.
Collegium Pharmaceutical vs. Its Competitors
Scholar Rock (NASDAQ:SRRK) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.
Scholar Rock has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
91.1% of Scholar Rock shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Scholar Rock currently has a consensus price target of $48.50, suggesting a potential upside of 72.17%. Collegium Pharmaceutical has a consensus price target of $42.33, suggesting a potential upside of 19.72%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Collegium Pharmaceutical.
In the previous week, Scholar Rock had 7 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 9 mentions for Scholar Rock and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.69 beat Scholar Rock's score of 0.25 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.
Collegium Pharmaceutical has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Collegium Pharmaceutical has a net margin of 5.13% compared to Scholar Rock's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 97.28% beat Scholar Rock's return on equity.
Summary
Collegium Pharmaceutical beats Scholar Rock on 9 of the 17 factors compared between the two stocks.
Get Collegium Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Collegium Pharmaceutical Competitors List
Related Companies and Tools
This page (NASDAQ:COLL) was last updated on 10/21/2025 by MarketBeat.com Staff
Free COLL Stock Alerts